TNF and heart failure: A clinical trial to assess the safety and efficacy of losmapimod, a p38 inhibitor, has been initiated, however, it was stopped when non-encouraging trials of the Tumor Necrosis Factor-α (TNF-α)-targeting [whose cardio-depressant action is induced by activation of p38 (193)] in heart failure patients were reported (194) [reviewed by Javed and Murtaza (195)].